Clinical Trial Update: Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study [Phase 1, Phase 2]

View source ↗

Summary

Long-term follow-up update from BP-004 study (Phase 1/Phase 2) by Bellicum Pharmaceuticals; study status TERMINATED with results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Aplastic Anemia
• Cytopenia
• Diamond-blackfan Anemia
• Fanconi Anemia
• Hemoglobinopathies
• Immunodeficiency
• Myelodysplastic Syndromes
• Non-hodgkin Lymphoma
• Sickle Cell Disease
• Thalassemia

Snippet

Sponsor: Bellicum Pharmaceuticals | Conditions: Acute Lymphoblastic Leukemia, Leukemia, Acute Myeloid (AML), Child | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2023-09-26